These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

537 related items for PubMed ID: 30864505

  • 1. Biosimilars of Adalimumab in Inflammatory Bowel Disease: Are we Ready for that?
    Argollo M, Fiorino G, Gilardi D, Furfaro F, Roda G, Loy L, Allocca M, Peyrin-Biroulet L, Danese S.
    Curr Pharm Des; 2019; 25(1):7-12. PubMed ID: 30864505
    [Abstract] [Full Text] [Related]

  • 2. Biosimilars of adalimumab: the upcoming challenge in IBD.
    Fiorino G, Gilardi D, Correale C, Furfaro F, Roda G, Loy L, Argollo M, Allocca M, Peyrin-Biroulet L, Danese S.
    Expert Opin Biol Ther; 2019 Oct; 19(10):1023-1030. PubMed ID: 30601098
    [Abstract] [Full Text] [Related]

  • 3. Comparison of Performances of Adalimumab Biosimilars SB5, ABP501, GP2017, and MSB11022 in Treating Patients with Inflammatory Bowel Diseases: A Real-Life, Multicenter, Observational Study.
    Tursi A, Mocci G, Allegretta L, Aragona G, Bianco MA, Colucci R, Cuomo A, Della Valle N, Ferronato A, Forti G, Gaiani F, Giorgetti G, Graziani MG, Lofano K, Lorenzetti R, Larussa T, Penna A, Pica R, Pranzo G, Rodino' S, Scarcelli A, Zampaletta C, Bassotti G, Cazzato AI, Chiri S, Clemente V, Cocco A, De' Angelis G, Donnarumma L, Faggiani R, Graziosi C, Le Grazie M, Luzza F, Meucci C, Monterubbianesi R, Pagnini C, Perazzo P, Picchio M, Sacco R, Sebkova L, Serio M, Napolitano D, Pugliese D, Scaldaferri F, Schiavoni E, Turchini L, Armuzzi A, Elisei W, Maconi G, Papa A.
    Inflamm Bowel Dis; 2023 Mar 01; 29(3):376-383. PubMed ID: 35579320
    [Abstract] [Full Text] [Related]

  • 4. Biosimilars in IBD: Will it Benefit to Patients, Physicians or the Health Care System?
    Gonczi L, Ilias A, Kurti Z, Lakatos PL.
    Curr Pharm Des; 2019 Mar 01; 25(1):13-18. PubMed ID: 30864504
    [Abstract] [Full Text] [Related]

  • 5. Belgian IBD Research Group [BIRD] Position Statement 2019 on the Use of Adalimumab Biosimilars in Inflammatory Bowel Diseases.
    Somers M, Bossuyt P, Ferrante M, Peeters H, Baert F.
    J Crohns Colitis; 2020 Jun 19; 14(5):680-685. PubMed ID: 31875891
    [Abstract] [Full Text] [Related]

  • 6. Review of Biosimilars of Adalimumab.
    Kaushik VV.
    J Assoc Physicians India; 2017 May 19; 65(5 Suppl):15-21. PubMed ID: 28836746
    [Abstract] [Full Text] [Related]

  • 7. Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach.
    Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, Kang T.
    Expert Rev Gastroenterol Hepatol; 2019 Aug 19; 13(8):731-738. PubMed ID: 31322440
    [Abstract] [Full Text] [Related]

  • 8. Biosimilar switching in inflammatory bowel disease: from evidence to clinical practice.
    Solitano V, D'Amico F, Fiorino G, Peyrin-Biroulet L, Danese S.
    Expert Rev Clin Immunol; 2020 Oct 19; 16(10):1019-1028. PubMed ID: 32954893
    [Abstract] [Full Text] [Related]

  • 9. Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts.
    Derikx LAAP, Dolby HW, Plevris N, Lucaciu L, Rees CS, Lyons M, Siakavellas SI, Constantine-Cooke N, Jenkinson P, Su S, O'Hare C, Kirckpatrick L, Merchant LM, Noble C, Arnott ID, Jones GR, Lees CW.
    J Crohns Colitis; 2021 Dec 18; 15(12):2011-2021. PubMed ID: 34089587
    [Abstract] [Full Text] [Related]

  • 10. Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD).
    Fiorino G, Caprioli F, Daperno M, Mocciaro F, Principi M, Viscido A, Fantini MC, Orlando A, Papi C, Annese V, Danese S, Vecchi M, Rizzello F, Armuzzi A, National patients’ association representatives.
    Dig Liver Dis; 2019 May 18; 51(5):632-639. PubMed ID: 30872085
    [Abstract] [Full Text] [Related]

  • 11. Biosimilars in ulcerative colitis: When and for who?
    Ilias A, Gonczi L, Kurti Z, Lakatos PL.
    Best Pract Res Clin Gastroenterol; 2018 May 18; 32-33():35-42. PubMed ID: 30060937
    [Abstract] [Full Text] [Related]

  • 12. Biosimilars in Inflammatory Bowel Disease: Facts and Fears of Extrapolation.
    Ben-Horin S, Vande Casteele N, Schreiber S, Lakatos PL.
    Clin Gastroenterol Hepatol; 2016 Dec 18; 14(12):1685-1696. PubMed ID: 27215364
    [Abstract] [Full Text] [Related]

  • 13. Review article: pharmacological aspects of anti-TNF biosimilars in inflammatory bowel diseases.
    Papamichael K, Van Stappen T, Jairath V, Gecse K, Khanna R, D'Haens G, Vermeire S, Gils A, Feagan BG, Levesque BG, Vande Casteele N.
    Aliment Pharmacol Ther; 2015 Nov 18; 42(10):1158-69. PubMed ID: 26365281
    [Abstract] [Full Text] [Related]

  • 14. Progress with infliximab biosimilars for inflammatory bowel disease.
    Kurti Z, Gonczi L, Lakatos PL.
    Expert Opin Biol Ther; 2018 Jun 18; 18(6):633-640. PubMed ID: 29688797
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and Safety of Adalimumab Biosimilars: Current Critical Clinical Data in Rheumatoid Arthritis.
    Lu X, Hu R, Peng L, Liu M, Sun Z.
    Front Immunol; 2021 Jun 18; 12():638444. PubMed ID: 33889152
    [Abstract] [Full Text] [Related]

  • 16. Switching From Originator Adalimumab to the Biosimilar SB5 in Patients With Inflammatory Bowel Disease: Short-term Experience From a Single Tertiary Clinical Centre.
    Lukas M, Malickova K, Kolar M, Bortlik M, Vasatko M, Machkova N, Hruba V, Duricova D, Lukas M.
    J Crohns Colitis; 2020 Jul 30; 14(7):915-919. PubMed ID: 31905382
    [Abstract] [Full Text] [Related]

  • 17. Efficacy, Safety and Immunogenicity of Biosimilars in Inflammatory Bowel Diseases: A Systematic Review.
    Martelli L, Peyrin-Biroulet L.
    Curr Med Chem; 2019 Jul 30; 26(2):270-279. PubMed ID: 27758715
    [Abstract] [Full Text] [Related]

  • 18. Adalimumab Biosimilars in the Treatment of Rheumatoid Arthritis: A Systematic Review of the Evidence for Biosimilarity.
    Huizinga TWJ, Torii Y, Muniz R.
    Rheumatol Ther; 2021 Mar 30; 8(1):41-61. PubMed ID: 33263165
    [Abstract] [Full Text] [Related]

  • 19. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S, Louis E, Dewit O, Franchimont D, Moreels T, Ferrante M, Rahier JF, Van Hootegem P, De Vos M, Mana F, Baert F, Belgian IBD Research & Development (BIRD).
    Acta Gastroenterol Belg; 2015 Mar 30; 78(1):26-9. PubMed ID: 26118575
    [No Abstract] [Full Text] [Related]

  • 20. SB5: An Adalimumab Biosimilar.
    Frampton JE.
    BioDrugs; 2018 Oct 30; 32(5):507-510. PubMed ID: 30251234
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 27.